{"protocolSection":{"identificationModule":{"nctId":"NCT07284797","orgStudyIdInfo":{"id":"XmAb657-01"},"organization":{"fullName":"Xencor, Inc.","class":"INDUSTRY"},"briefTitle":"A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflammatory Myopathy (IIM)","officialTitle":"A Phase 1, First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of XmAb657 in Healthy Participants and in Participants With Idiopathic Inflammatory Myopathy"},"statusModule":{"statusVerifiedDate":"2025-12","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2026-02","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2027-02","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-02","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-12-03","studyFirstSubmitQcDate":"2025-12-15","studyFirstPostDateStruct":{"date":"2025-12-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-15","lastUpdatePostDateStruct":{"date":"2025-12-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Xencor, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with IIM. Participants will be given XmAb657 subcutaneously (SC) by injection under the skin.","detailedDescription":"This is a Phase 1 study to determine the safety, tolerability, pharmacokinetic (PK), and pharmacodynamics (PD), and immunogenicity of XmAb657 in healthy adult participants and participants with IIM."},"conditionsModule":{"conditions":["Healthy","Idiopathic Inflammatory Myopathies"],"keywords":["Myopathy","Myositis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":27,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Dose Escalation","type":"EXPERIMENTAL","description":"XmAb657 administered SC","interventionNames":["Biological: XmAb13676"]}],"interventions":[{"type":"BIOLOGICAL","name":"XmAb13676","description":"Biological","armGroupLabels":["Dose Escalation"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)","timeFrame":"Through Week 24"}],"secondaryOutcomes":[{"measure":"Serum concentration of XmAb657","timeFrame":"Through Week 24"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nHealthy participants - Adult participants in good health\n\nIdiopathic inflammatory myopathy participants - Adult participants that meet the 2017 European Alliance of Association Rheumatology (EULAR)/American College of Rheumatology (ACR) classification of Idiopathic inflammatory myopathy\n\nIdiopathic inflammatory myopathy participants - Stable doses of Idiopathic inflammatory myopathy medications prior to screening\n\nAll participants - Use of highly effective methods of contraception\n\nExclusion Criteria:\n\n* Major surgery within 12 weeks prior to screening or planned within 12 months after dosing\n* Recurrent infections or active clinically significant infection\n* Active or untreated latent tuberculosis\n* Cancer or history of cancer or lymphoproliferative disease within the previous 5 years\n* Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease\n\nNote: Additional, more specific inclusion/exclusion criteria are defined in the protocol.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Noriko Iikuni, MD, PhD","role":"CONTACT","email":"657-AIinfo@xencor.com"},{"name":"Jaime Mertz","role":"CONTACT","email":"657-AIinfo@xencor.com"}],"overallOfficials":[{"name":"Mark Osterman, MD, MSCE","affiliation":"Xencor, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Xencor Investigative Site","city":"Melbourne","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D009220","term":"Myositis"},{"id":"D009135","term":"Muscular Diseases"}],"ancestors":[{"id":"D009140","term":"Musculoskeletal Diseases"},{"id":"D009468","term":"Neuromuscular Diseases"},{"id":"D009422","term":"Nervous System Diseases"}]}},"hasResults":false}